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Abstract
Background: Multiple types of extracellular vesicles (EVs), including microvesicles (MVs) and exosomes (EXOs), are
released by all cells constituting part of the cellular EV secretome. The bioactive cargo of EVs can be shuffled
between cells and consists of lipids, metabolites, proteins, and nucleic acids, including multiple RNA species from
non-coding RNAs to messenger RNAs (mRNAs). In this study, we hypothesized that the mRNA cargo of EVs could
differ based on the EV cellular origin and subpopulation analyzed.
Methods: We isolated MVs and EXOs from PC-3 and LNCaP prostate cancer cells by differential centrifugation and
compared them to EVs derived from the benign PNT2 prostate cells. The relative mRNA levels of 84 prostate cancer-
related genes were investigated and validated using quantitative reverse transcription PCR arrays.
Results: Based on the mRNA abundance, MVs rather than EXOs were enriched in the analyzed transcripts, providing a
snapshot of the tumor transcriptome. LNCaP MVs specifically contained significantly increased mRNA levels of NK3
Homeobox 1 (NKX3-1), transmembrane protease serine 2 (TMPRSS2), and tumor protein 53 (TP53) genes, whereas PC-3
MVs carried increased mRNA levels of several genes including, caveolin-2 (CAV2), glutathione S-transferase pi 1 (GSTP1),
pescadillo ribosomal biogenesis factor 1 (PES1), calmodulin regulated spectrin associated protein 1 (CAMSAP1), zinc-
finger protein 185 (ZNF185), and others compared to PNT2 MVs. Additionally, ETS variant 1 (ETV1) and fatty acid
synthase (FASN) mRNAs identified in LNCaP- and PC-3- derived MVs highly correlated with prostate cancer progression.
Conclusions: Our study provides new understandings of the variability of the mRNA cargo of MVs and EXOs from
different cell lines despite same cancer origin, which is essential to better understand the the proportion of the cell
transcriptome that can be detected within EVs and to evaluate their role in disease diagnosis.
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Background
Extracellular vesicles (EVs) are membrane-derived particles
released under normal conditions by many cell types to
eliminate non-desired cell components and to share infor-
mation between cells and their environment [1, 2]. EVs are
considered to play important roles in cell-to-cell communi-
cation, contributing to changes in the recipient cell
phenotypes by influencing their functions, which is of spe-
cial relevance for instance in the hallmarks of cancer [3, 4].
Cells release a diverse mixture of EVs that can be consid-
ered as the cellular EV secretome [5–7]. Most notable sub-
populations of EVs are microvesicles (MVs) and exosomes
(EXOs), both released by viable cells under normal physio-
logical conditions. Current state of the art classification
considers MVs to have a diameter of 100–1,000 nm, and
being primarily derived from the cell surface by budding of
the plasma membrane, whereas EXOs are smaller, 30–150
nm, and are formed within the multivesicular bodies which
liberate EXOs to the extracellular space by fusion with the
plasma membrane [8]. Importantly, EVs contain a broad
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variety of signaling molecules that reflect the composition
of their originator cells including lipids, proteins, metabo-
lites, sugars, and particularly nucleic acids [2, 8]. These
molecules can be functionally delivered mediating bio-
logical activities and functional changes in the recipient
cells [9–12]. Interestingly, the EV cargo only partly reflects
the cells of origin, and especially EXOs have been shown to
carry different RNA species compared to the producing
cells [9, 10, 13–15].
Several RNA molecules, including messenger RNAs
(mRNAs) and non-coding RNAs (ncRNAs), particularly
microRNAs (miRNAs) but also transfer RNAs and other
ncRNAs, have been investigated from EVs of different
origins [15–17]. MVs and EXOs share functional fea-
tures, and to a large extent, molecular composition.
However, they are still distinct subpopulations of EVs
that are likely to mediate different actions. As the most
common methods of vesicle isolation do not allow sep-
aration of EV subsets, most EV studies have not com-
pared MVs and EXOs, and hence a very limited number
of reports have so far compared the cargo differences of
the EV subtypes [5, 6, 18–20].
We hypothesized that the mRNA content of EVs differs
based on the EV subpopulation analyzed and the cellular
origin of the EVs. Moreover, we focused on the compari-
son of the mRNA cargo of MVs and EXOs from different
prostate cancer (LNCaP and PC-3) and benign (PNT2)
cells, since such comparison has so far not been
performed. Quantitative reverse transcription PCR (RT-
qPCR) mRNA arrays were used to characterize and valid-
ate the mRNA signatures of 84 prostate cancer (PCa)
related genes in the EVs. We analyzed mRNAs known to
be related to PCa, as such data could provide new insights
for understanding the differential mRNA content of EV
subpopulations which may be of future clinical use.
Methods
Cell culture
LNCaP and PC-3 (ATCC, Manassas, VA, USA) were
grown in RPMI 1640 and DMEM/F12 media (Sigma-Al-
drich, St Louis, MO, USA), respectively. Both media were
supplemented with 10% (v/v) EV-depleted FBS (Sigma-Al-
drich). The FBS was EV-depleted by ultracentrifugation at
118,000 x gavg for 18 h using a type 45 Ti rotor k-factor
178.6 (Beckmann Coulter, Brea, CA, USA), followed by fil-
tration through a 0.22 μm filter (Merck Millipore, Biller-
ica, Massachusetts, USA). Immortalized human benign
prostate epithelial cells PNT2 (ECACC, Sigma-Aldrich)
were grown in serum-free defined keratinocyte media,
supplemented with bovine pituitary extract and human re-
combinant epidermal growth factor (Life Technologies,
Carlsbad, CA, USA). All media were supplemented with
100 IU/mL of penicillin and 100 μg/mL streptomycin
(HyClone, Logan, UT, USA). Cells were cultivated at 37 °C
and 5% CO2. Cell viability was measured by Trypan Blue
solution (Sigma-Aldrich). Cells were routinely checked for
mycoplasma contamination using the MycoAlert™ PLUS
(Lonza Walkersville, MD, USA).
Extracellular vesicle isolation
Three hundred mL of cell cultured conditioned media
was harvested from LNCaP, PC-3, and PNT2 cells at 80%
confluence, and centrifuged at 1,000 x g at 4 °C for 10 min
to remove remaining cells and cellular debris. The
remaining supernatant was centrifuged at 2,500 x g for
25 min at 4 °C to pellet larger vesicles such apoptotic bod-
ies. The supernatant was transferred to new tubes and
centrifuged at 20,000 x gavg for 25 min at 4 °C to pellet the
MV-enriched fractions. The final supernatant was ultra-
centrifuged at 110,000 x gavg, for 2 h using an Optima XE
90 ultracentrifuge, 45 Ti rotor and polyallomer centrifuge
tubes (Beckman Coulter) k-factor 191.3, to pellet the
EXO-enriched fractions. All vesicle pellets were resus-
pended in PBS or lysis buffer depending on the down-
stream analysis and stored at -80 °C.
Transmission electron microscopy
MV and EXO samples (6 μL) were incubated onto glow
discharged 200 mesh formvar copper grids (Electron Mi-
croscopy Science) for 2 min at 4 °C. The grids were
washed and blotted dry with filter paper. Next, the grids
were negatively stained with 2% aqueous uranyl acetate
(Sigma-Aldrich), washed with distilled water and dried in
darkness. The grids were visualized using a transmission
electron microscope (FEI Tecnai Spirit G2) at 80 kV. Im-
ages were taken by a digital camera (Soft Image System,
Morada).
Western blot analysis
EVs and cells were lysed with RIPA buffer (Pierce, Thermo
Scientific, Rockford, IL, USA) and sonicated three times for
five minutes with intermittent vortexing in between. Pro-
tein concentration was determined by using the BCA Pro-
tein assay following manufacturer´s recommendations
(Pierce, Thermo Scientific). Then, 30 μg of protein of cellu-
lar lysates and EVs were loaded on a 10% polyacrylamide
gel and transferred onto a nitrocellulose membrane (Bio-
Rad laboratories, Hercules, CA, USA). Membranes were
blocked with 5% Blotting-Grade Blocker Non-Fat Dry Milk
(Bio-Rad Laboratories) in Tris-buffer saline (TBS) for 1 h.
Membranes were incubated with the following primary
antibodies dissolved in 0.25% Blotting-Grade Blocker Non-
Fat Dry Milk in TBS-0.5% Tween-20 (TBST) against: cal-
nexin (1:1000; clone H-70), CD81 (1:800; clone H-121;),
and flotillin-1 (1:1000; clone H-104) all from Santa Cruz
Biotechnology (Santa Cruz, CA, USA) at 4 °C overnight.
The membranes were washed three times with TBST, and
incubated for 1 h at room temperature with the secondary
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antibody (1:10,000) ECL donkey anti-rabbit IgG horseradish
peroxidase-linked F(ab’)2fragment (GE Healthcare,
Buckinghamshire, UK), diluted in 0.25% Milk in TBST. The
membranes were washed three times with TBST and
analyzed with ECL Prime Western Blotting Detection (GE
Healthcare) and a VersaDoc 4000 MP (Bio-Rad
Laboratories).
RNA extraction and profiling
Total RNA from cells and EV subpopulations was iso-
lated using the miRNAeasy micro kit (Qiagen, Hilden,
Germany), according to the manufacturer´s instructions.
RNA samples were eluted in 14 μL of RNAse-free water,
aliquoted, and stored at -80 °C. The quality and sized of
the isolated RNA was measured by capillary electrophor-
esis using an Agilent Bioanalyzer 2100 (Agilent Tech-
nologies, Santa Clara, CA, USA). RNA from each
sample was denatured at 72 °C for 2 min and loaded into
RNA 6000 Nano and Pico total RNA kits (Agilent Tech-
nologies) to analyze RNA profile and concentration. The
RNA concentration was used as a normalizing loading
factor for all EV samples.
Reverse transcription and pre-amplification
RNA samples were subjected to genomic DNA removal;
cDNA synthesis, and instant preamplification using the
RT2 PCR System PreAMP and Human Prostate Cancer
Pathway mix (Qiagen, Hilden, Germany), following the
manufacturer’s recommendations. Next, pre-amplified
cDNA was quantified by using Bioanalyzer 2100 and
Nanodrop 1000 (Thermo Scientific) and input to the
PCR arrays was normalized to 100 ng/μL for all samples.
Reverse transcription quantitative PCR (RT-qPCR)
The PAHS-135Z Human Prostate Cancer Pathway RT2
Profiler PCR Arrays (SABiosciences, Qiagen) were used
to analyze all vesicle samples, following the protocol´s
instructions. For each sample type, three assays were
carried out as independent biological replicates. In sum-
mary, 100 ng/μL of pre-amplified cDNA from LNCaP-,
PC-3- and PNT2- derived MVs and EXOs were mixed
with the RT2 SYBR Green Mastermix and RNAse-free
water. Aliquots of the PCR component mix (25 μL) were
distributed across the array. The plates were sealed, cen-
trifuged 1 min at 1,500 x g to remove air bubbles, and
run in a CFX96 thermocycler (Bio-Rad). The cycling
conditions were as follows: 95 °C for 10 min; 40 cycles
(95 °C for 15 sec, 60 °C for 1:00 min). The Ramp rate be-
tween the 95 °C to 60 °C step was 1 °C/sec and the same
threshold was used across the arrays. Each array con-
tained inter-plate and reverse transcription calibrators as
well as a gDNA contamination control.
mRNA data analysis
Raw cycle threshold (Ct) values were exported and ana-
lyzed by using the PCR Array Data Analysis Software
version 3.5, provided by SABiosciences. Gene mRNA
level was related to the mean mRNA levels of all the
genes present across the samples. Only Ct values < 35
were included in the analysis. Calculations of relative ex-
pression were performed with the 2−ΔΔCT method [21].
Student’s t-test was used to calculate the P values of the
replicate 2−ΔCt values for each gene in the control and
sample groups. P values of less than 0.05 were consid-
ered statistically significant. A fold-change threshold of
10 was used for the stringent analysis. Results are shown
as the mean ± SEM of three samples for each condition
in relation to the mean ± SEM of three control samples
for each group. All statistical analyses were performed
using the statistical software package, GraphPad Prism
7.0 (GraphPad Software, Inc., San Diego, CA, USA).
Results
Differential RNA profiles in the subpopulations of EVs
from PCa and non-cancerous cells
Using differential centrifugation, we isolated both MVs and
EXOs from two common PCa cell lines (LNCaP and PC-3),
and a benign prostate epithelial cell line (PNT2). Transmis-
sion electron microscopy characterization showed that MVs
were more heterogeneous in size and morphology than
EXOs, ranging in sizes from> 200 nm, while the EXOs var-
ied between 30–150 nm (Fig. 1a). Additionally, no evident
differences were observed in EV morphology among the
three cell lines analyzed. The membrane proteins CD81 and
flotillin-1 (common EV markers) were detected in both EV
subpopulations by Western blotting with a higher enrich-
ment in the EXO fractions compared to MVs. The endo-
plasmic reticulum marker calnexin was highly enriched in
cell samples, compared to EV fractions (Fig. 1b).
To determine whether EVs isolated from the PCa and
non-cancerous cell lines had distinct RNA profiles, we
analyzed the total RNA content and length from their
MVs and EXOs using a Bioanalyzer 2100 instrument
(Fig. 1c). MVs from all three samples had clear and dis-
tinct peaks at around 2,000 and 4,000 nucleotides (nt)
which represent the 18S and 28S ribosomal RNA
(rRNA) respectively, with relatively moderate levels of
small RNAs. In contrast, EXOs were primarily enriched
in small RNAs but also contained larger RNA molecules,
especially in the PNT2 EXOs RNA profile. MV and
EXO RNAs from both PCa cell lines had similar profiles
and size distributions. On the other hand, MVs and
EXOs derived from non-cancerous cells had very similar
RNA profiles between subpopulations but different RNA
profiles compared with the cancer-derived EVs, suggest-
ing that the RNA content of EVs from distinct cellular
origins significantly varies.
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MVs and EXOs from different cell lines have unique
mRNA signatures
As the RNA profiles found in the EV subpopulations
seem to represent a diverse selection of RNA species, we
decided to focus further analyses on the mRNA content
of EVs. For that purpose, we used a human PCa pathway
qPCR array approach, which covers 84 mRNA tran-
scripts of genes known to be involved in PCa (Fig. 2 and
Additional file 1: Figure S1). First, we determined the
percentage of genes detected in the different groups by
the presence of specific mRNAs. Close to 100% of these
mRNAs were detected in MVs from both LNCaP and
PC-3 cells, whereas less than 50% of the mRNAs studied
were identified in MVs from the PNT2 cells. Addition-
ally, the abundance of the different transcripts analyzed
was more variable in EXOs than in MVs among the
different donor cells, as observed by the Ct values
(Additional file 1: Figure S1). Overall, the Ct values
obtained from the analysis were lower in the MVs
compared to the EXOs in all samples, suggesting an
enrichment of these mRNAs in MVs.
To examine whether distinct mRNA patterns were ob-
served in EVs derived from different PCa cells, we com-
pared the transcripts present in LNCaP and PC-3 cell-
derived MVs and EXOs (Fig. 2). The differences in mRNAs
abundances are shown as a scatter plots in Fig. 2a, b, with
the cut-off lines being 10-fold change. We used this strict
limit to focus on transcripts with obvious differences
among the samples. The mRNA transcripts from ten genes
were shown to be unique for LNCaP MVs, and ten different
mRNA transcripts were also specific for PC-3 MVs (Fig. 2c).
On the other hand, six transcripts were unique for LNCaP
EXOs, and seven other mRNA transcripts were exclusive of
PC-3 EXOs (Fig. 2d).
Among the commonly found mRNAs that were
differentially present in both MVs and EXOs for each
cell line, LNCaP samples showed significant increases of
kallikrein-related peptidase 3 (KLK3) (also known as
Fig. 1 Characterization of the EV subpopulations isolated from prostate cell lines. a Representative electron microscopy pictures of microvesicles (MVs)
and exosomes (EXOs) isolated from LNCaP, PC-3 and PNT2 cells by differential centrifugation. Scale bars represent 200 nm. b Presence of calnexin (an
endoplasmic reticulum marker), flotillin-I, and CD81 (EV markers) analyzed by Western blotting. An equal protein amount of 30 μg was loaded of all
the samples. c RNA profiles of MVs and EXOs isolated from LNCaP, PC-3, and PNT2 cells after total RNA extraction. Profiles analyzed by capillary
electrophoresis with the Agilent RNA 6000 Nano and Pico Total RNA kits. Representative electropherograms showing in the y-axis fluorescence units
(FU) and in the x-axis the nucleotide length (nt) of the RNA. Peaks at 25 nt represent internal standards and peaks at 2,000 nt and 4000 nt represent
ribosomal RNA 18 and 28 subunits, respectively. The panels A-C are representative of 3 independent experiments showing the same trends of vesicle
morphology, size, and presence of the selected markers
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prostate-specific antigen: PSA) related to PCa neoplastic
growth and metastasis [22]; NK3 Homeobox 1 (NKX3-1),
an androgen-regulated transcription factor indicating poor
prognosis [23]; the transmembrane protease serine 2
(TMPRSS2), a gene which is up-regulated by androgenic
hormones [23]; the tissue inhibitor of metalloproteinase-3
gene (TIMP3), a tumor suppressor gene frequently down-
regulated in PCa [24]; and tumor protein 53 (TP53), the
well-known tumor suppressor gene. In contrast, for PC-3
MVs and EXOs a common increase in the mRNA levels
of several genes was found, including caveolin-1 (CAV1),
reportedly overexpressed in PCa and associated with
disease progression [25, 26]; caveolin-2 (CAV2), a gene
involved in cell cycle [27]; glutathione S-transferase pi 1
(GSTP1) and cyclin-dependent kinase inhibitor 2A
(CDKN2A), both genes showing differentially methylated
promoters and involved in cancer progression [28, 29];
and tissue factor pathway inhibitor 2 (TFPI2), a gene usu-
ally down-regulated in PCa cells [30]. These differences
between EVs based on their source of origin defined their
specific mRNA signature.
mRNA transcripts associated with PCa can be variably
detected in EV subpopulations
A hierarchical clustering analysis of the most signifi-
cantly differing mRNAs in MVs and EXOs across the
groups was performed in order to evidence the abun-
dance pattern of each sample (Fig. 3a). The PCa cell-
derived EV subpopulations had more similarities with
each other compared with the non-cancerous EVs,
and the obtained clustering pattern reflected their
differences of cellular origin (cancerous vs non-
cancerous cells) (Fig. 3a). Next, the relative mRNA
levels between MVs and EXOs in comparison with
their respective EV control from the benign cells were
examined. Volcano plots showed significances (as a
negative log P values) vs means of differential fold
changes for the comparisons of LNCaP MVs vs PNT2
MVs (Fig. 3b), LNCaP EXOs vs PNT2 EXOs (Fig. 3c),
PC-3 MVs vs PNT2 MVs (Fig. 3d), and PC-3 EXOs
vs PNT2 EXOs (Fig. 3e). Using a cut-off threshold of
10-fold change and a P value of 0.05, the number of
genes classified based on their relative abundance on
the study groups compared with the control group
was similar [LNCaP MVs: 21/9, LNCaP EXOs: 4/3,
PC-3 MVs: 25/12, PC-3 EXOs; 5/3 (up/down)].
Comparison of MVs and EXOs showed that MVs were
enriched in the studied mRNAs compared to the EXOs
for both cell lines (Fig. 3b-e). Furthermore, the statisti-
cally significant mRNA transcripts in EXOs samples
were also present in the MVs. In view of both the RNA
concentration and the transcript enrichment, MVs were
Fig. 2 Prostate cancer-derived MVs and EXOs have unique mRNA signature resembling their origin. Scatter plots depicting a log transformation of the
relative mRNA level of each gene (2-ΔCt) between: (a) LNCaP MVs (y-axis) and PC-3 MVs (x-axis) and (b) LNCaP EXOs (y-axis) and PC-3 EXOs (x-axis). The
gray lines indicate a boundary of 10. Genes at prominent coordinates are annotated. Data are representative of three independent experiments per
group. Fold-change cut-off =10. (c, d) Venn diagrams representing common and unique mRNAs of the genes detected in LNCaP and PC3 MVs and
LNCaP and PC-3 EXOs respectively
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selected to further study the differences in the mRNA
levels known to be associated with PCa.
MVs contained differential PCa-associated mRNAs
To compare the studied MVs from the different origins in
depth, we examined the differential mRNA abundance
across all the MV samples (Fig. 4). For both LNCaP and
PC-3 MVs, there was a 55.8% overlap in mRNA tran-
scripts when compared to PNT2 MVs (Fig. 4a). Addition-
ally, mRNAs were classified as enriched either exclusively
in the LNCaP MVs or PC-3 MVs, or to be common for
both the PCa vesicle types (Additional file 2: Table S1,
Additional file 3: Table S2 and Additional file 4: Table S3).
The statistically significant mRNA transcripts for LNCaP
MVs (Fig. 4b) and PC-3 MVs (Fig. 4c) are presented. The
analysis of the fold differences between groups showed
that the mRNA abundance of 30 genes in the LNCaP
MVs (16 statistically significant) and 37 in the PC-3 MVs
(32 statistically significant) was different from the control
PNT2 MVs. For LNCaP MVs, mRNA levels of ETS variant
1 (ETV1), fatty acid synthase (FASN), NKX3-1, RNA-
binding protein 39 (RBM39), TMPRSS2, and TP53 genes
were increased, while mRNA levels of CAV1, cyclin D2
(CCND2), ETS-related gene (ERG), forkhead box protein
O1 (FOXO1), gonadotropin releasing hormone 1 (GNRH1),
GSTP1, histidine ammonia-lyase (HAL), lectin, galactoside
binding soluble 4 (LGALS4), suppressor of cytokine signal-
ing 3 (SOCS3), and tissue factor pathway inhibitor 2
(TFIPI2) genes were decreased when compared to PNT2
MVs (Fig. 4b). From PC-3 MVs, increased mRNA levels of
calmodulin regulated spectrin associated protein 1 (CAM-
SAP1), CAV1, CAV2, cyclin D1 (CCND1), ETV1, FASN,
GSTP1, nuclear receptor interacting protein 1 (NRIP1), pes-
cadillo ribosomal biogenesis factor 1 (PES1), RBM39,
TFPI2, ZNF185 were detected, whereas mRNA levels of an-
drogen receptor (AR), CCND2, dickkopf WNT signaling
pathway inhibitor 3 (DKK3), endothelin receptor type B
(EDNRB), early growth response 3 (EGR3), GNRH1,
Fig. 3 Comparison of the differences in the mRNA levels associated with MVs and EXOs. a Non-supervised hierarchical clustering indicating
normalized enrichment of the mRNA levels of the 46 most significant genes detected in the LNCaP and PC-3 MVs and EXOs in comparison with
the PNT2 MVs or PNT2 EXOs. Volcano plots indicating changes in mRNA levels between: (b) LNCaP MVs vs PNT2 MVs; (c) LNCaP EXOs vs PNT2
EXOs; (d) PC-3 MVs vs PNT2 MVs; and (e) PC-3 EXOs vs PNT2 EXOs. Data is representative of three independent experiments per group. Data is
reported as x-axis = log2 (fold change of sample/Ctrl), y-axis = negative log10 (P value). The horizontal blue line indicates a P value of 0.05. The
vertical grey line indicates an absolute fold-change of 10. Red and green dots indicate increased or decreased mRNA levels of the genes of study
in the MVs and EXOs in comparison to the PNT2 MVs and EXOs
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glutathione peroxidase 3 (GPX3), HAL, insulin like growth
factor 1 (IGF1), insulin like growth factor binding protein 5
(IGFBP5), LGALS4, phosphatase and tensin homolog
(PTEN), prostaglandin G/H synthase and cyclooxygenase
(PTGS1), retinoic acid receptor beta (RARB), secreted
frizzled-related protein 1 (SFRP1), sex hormone binding
globulin (SHBG), solute carrier family 5 member 8
(SLC5A8), TMPRSS2, tumor necrosis factor receptor super-
family member 10d (TNFRSF10D) were decreased when
compared to PNT2 MVs (Fig. 4c). Overall, when analyzing
the statistically significant changes in the mRNA abundance
and the overlap between the normalized samples, eight
mRNAs were found to be unique for LNCaP MVs, 17 were
exclusive for PC-3 MVs, and only eight mRNAs were sig-
nificantly abundant and common for MVs from both PCa
cell lines (Fig. 4d and Additional file 2: Table S1, Additional
file 3: Table S2 and Additional file 4: Table S3). This argues
that different cancer cell lines from the same cancer type
can release a vesicular secretome carrying fundamentally
different mRNA transcripts.
Next, we determined which of the common mRNAs
for both the PCa MVs had statistically significant differ-
ent levels compared to the control PNT2 MVs (Table 1).
PCa vs control comparisons revealed some startling in-
creases of mRNA levels of: ETV1, a gene that directs an-
drogen metabolism and confers aggressive PCa [23];
FASN, a fatty acid metabolism gene highly up-regulated
in PCa [31]; RBM39, a gene implicated in colorectal and
breast cancer progression [32, 33]. On the other hand,
we also observed decreases in the mRNA levels of genes
such as CCND2, a crucial cell cycle-regulatory gene
down-regulated in PCa cells [34]. Interestingly, the levels
of the transcription factor ERG whose up-regulation is a
poor prognosis indicator [23], and GNRH1, HAL, and
LGALS4 genes were decreased in the PCa-derived MVs.
Differential expression of the mRNAs in other EVs,
prostate cancer cell lines, and prostate biopsies
To evaluate the presence of the common PCa mRNAs
identified in LNCaP and PC-3 MVs in EVs from different
Fig. 4 Prostate cancer associated mRNA analysis in MVs. a Venn diagram representing increased (red) and decreased (green) mRNA levels of prostate
cancer (PCa) pathway genes in the LNCaP- and PC-3 MVs vs the PNT2 MVs (Ctrl). RT-qPCR data showing the statistically significant fold changes of
particular genes in (b) LNCaP MVs vs Ctrl (c) PC-3 MVs vs Ctrl. Data are reported as the log2 of the fold change relative to the Ctrl. Fold-change cut-off =10.
Bars represent the mean ± SEM of three independent experiments per group. *P <0.05, **P <0.01, ***P <0.001. d Venn diagram representing a summary
the statistically significant mRNAs of the analyzed genes after comparison with the Ctrl, exclusively present in LNCaP MVs and PC-3 MVs. The mRNAs that
were significantly common for both samples are also represented
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sources, a comparison was performed with all the studies
collected in EVpedia were these mRNAs were identified in
EVs [35] (Fig. 5a). A very limited number of reports (2–4
out of 11) identified the mRNAs in EVs from different
cancer and non-cancerous cell sources, with the exception
of FASN, which was found in 6/10 studies. Interestingly,
LGALS4 mRNA has been first identified and validated in
this study. To further assess whether the statistically
significant common mRNAs found in PCa MVs were cell-
line specific and represented specific PCa signatures, we
compared them with a publically available dataset
(GSE36720) in the GEO database of mRNAs expressed in
different PCa cell lines (Fig. 5b). CDH1, NKX3-1, and
TP53 genes were over-expressed in LNCaP cells compared
with PC-3 cells. Contrary, CAV2, GSTP1, TFPI2, and
ZNF185 genes were over-expressed in PC-3 cells in com-
parison with LNCaP cells, and ETV1, FASN, CCND2,
ERG, GNRH1, HAL, and LGALS4 genes exhibited similar
expression in both cell lines. Finally, as a proof of concept
to evaluate the possible clinical relevance of the common
mRNAs for both PC-3 and LNCaP MVs, the results were
compared with a publically available microarray dataset in
the GEO database containing information of mRNA
expression on benign and malignant prostate tissue
(GSE55945) (Fig. 5c). Here, some of the significant com-
mon mRNAs discovered in the PCa MVs, including ETV1
and FASN genes, were significantly differentially expressed
in the malignant prostate tissue in comparison with the
benign tissue. This finding suggests that the mRNAs from
ETV1 and FASN genes found to be significantly enriched
in MVs from LNCaP and PC-3 cells correlated with pros-
tate cancer in patient samples, demonstrating the possible
future applicability of the mRNA analysis using MVs.
Discussion
In this study, we analyzed the mRNAs of 84 genes known
to be involved in PCa from EV subpopulations derived from
human PCa cell lines. LNCaP and PC-3 cells were chosen
for EV isolation due to their extensive use as PCa cell
models. To compare the relative abundance of mRNAs in
EVs, the same subpopulations were isolated from PNT2
cells, a benign human prostatic epithelial cell line [36]. Dif-
ferential centrifugation, the gold standard technique in the
EV isolation [37], allowed the separation of enriched MVs
and EXOs fractions, as previously reported [20, 38]. Despite
its drawbacks, differential centrifugation is still the only
technique that results in the separation of enriched, larger
and smaller EV subpopulations albeit overlapping and non-
homogeneous. PCa MVs and EXOs carried common EV
proteins irrespective of being derived from malignant or
non-malignant cells, and they had similar morphology and
size range independent of their cellular origin, as described
by our group [5, 6, 20, 38] and others [7, 39].
EVs from both normal and cancer cells can carry both
intact and fragmented mRNA with a size range between
25 and 700 nt, which is considerably different from the in-
tact cellular mRNAs, sized between 400 nt to 12,000 nt
[40–42]. The presence of 18S and 28S rRNA in EVs has
been reported rather ambiguously. In our study, and con-
sistent with what others have previously published, MVs
contained significantly more rRNA than EXOs, which
were primarily enriched in smaller RNAs of < 700 nt, des-
pite the presence of larger RNA fragments [5–7]. How-
ever, the PNT2-derived EXOs had a bigger proportion of
rRNA than the EXOs from PC-3 and LNCaP cells, which
may imply that specific RNA sorting signals and mecha-
nisms exist for distinct subtypes of EVs or originator cells
[14, 16, 43–46].
RNA signatures of EVs can be specific for the cells of
their origin [36, 42] discriminating e.g. the cancerous
transformation status of cells. In this study, MVs were
found to be significantly enriched in several of the mRNAs
analyzed when compared to EXOs. Based on these results,
MVs rather than EXOs might better represent a
Table 1 Top Commonly Regulated Genes between LNCaP MVs and PC-3 MVs vs PNT2 MVs
LNCaP MVs PC-3 MVs
Gene Symbol Name Unigene ID RefSeq Log FC P Value Log FC P Value
Up-regulated
ETV1 Ets variant 1 Hs.574240 NM_004956 4.3 0.042 3.4 0.02
FASN Fatty acid synthase Hs.83190 NM_004104 5.3 0.016 5.8 0.01
RBM39 RNA binding motif protein 39 Hs.282901 NM_004902 4.7 0.027 5.3 <0.001
Down-regulated
CCND2 Cyclin D2 Hs.376071 NM_001759 −7.7 0.030 −6.2 0.031
ERG V-ets erythroblastosis virus E26 oncogene homolog (avian) Hs.473819 NM_182918 −4.3 0.049 −7.3 0.041
GNRH1 Gonadotropin-releasing hormone 1 (luteinizing-releasing hormone) Hs.82963 NM_000825 −4.0 0.029 −4.5 0.024
HAL Histidine ammonia-lyase Hs.190783 NM_002108 −5.7 <0.001 −6.3 <0.001
LGALS4 Lectin, galactoside-binding, soluble, 4 Hs.5302 NM_006149 −4.1 0.034 −3.6 0.037
Log2 fold-change (mean of the differential mRNA levels); P value for the differential mRNA levels
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population of vesicles with an advantage for translational
studies. Since MVs are larger vesicles, they might also
contain more tumor-derived molecules including metabo-
lites, proteins, and nucleic acids. Moreover, the RNA pro-
file of MVs seems to be more similar to the donor cells
than that of EXOs [5, 6], thereby giving a snapshot of the
tumor transcriptome. This is an important finding, since
the emphasis of EVs in cancer research has so far heavily
been on EXOs and only a few studies have highlighted the
advantages of larger vesicles, including large oncosomes
[47]. However, more research is needed in order to eluci-
date whether tumor cells modulate the EV cargo at differ-
ent stages of the disease and how the specific sorting of
molecules into EVs takes place.
Here, the relative abundance of mRNAs was analyzed
for different types of genes associated with PCa: differen-
tially methylated promoters, androgen-signaling pathway,
PI3 kinase/AKT and PTEN signaling pathways, apoptosis,
cell cycle, and metastatic potential. Among them, statis-
tical significant mRNA levels of 16 genes were at least 10-
fold differentially regulated in the LNCaP MVs and 32 in
PC-3 MVs when compared to the control PNT2 MVs.
Interestingly, mRNAs sequences of only three genes were
uniquely increased in LNCaP MVs in comparison with
PNT2 MVs. These included the NKX3-1 gene, which is
one of the earliest markers for prostate development dur-
ing embryogenesis and is a regulator of cell proliferation,
differentiation, and apoptosis [23]; the TP53 gene, which
is well-known for tumor recurrence and metastasis [48],
and the androgen-regulated TMPRSS2 gene, which is
highly expressed in PCa [49, 50]. In contrast, eight
mRNAs were exclusively present in PC-3 MVs, some of
them include CAV2 gene, a cell cycle regulator involved in
PCa progression [27]; the GSTP1 gene, whose hyperme-
thylation is one of the most frequently observed aberra-
tions in PCa [28]; PES1, CAMSAP1, and CCND1 genes,
up-regulated or correlated with PCa development [51–53]
and the ZNF185 gene, which is frequently reported to be
dysregulated in PCa [54]. Overall, the unique mRNA sig-
nature of LNCaP and PC-3 MVs allows the discrimination
Fig. 5 Comparative analysis of MV-mRNAs previously identified in other EVs, prostate cancer cell lines, and prostate benign and malignant tissues.
a Heat map displaying the presence (blue) or absence (white) of the eight commonly identified mRNAs for the ETV1, FASN, RBM39, CCND2, ERG,
GNRH1, HAL and LGALS4 genes in eleven different microarray studies of mRNA content of EVs from EVpedia database. blue = identified with a false
positive ration (FPR) <0.05; light blue = identified with a FPR >0.05; white = not identified. b Heat map showing the expression of 14 genes in
LNCaP, PC-3 and DU-145 cell lines from a dataset with accession number GSE36720. c Heat map displaying the differential expression of the
mRNAs of eight genes in malignant prostate tissue as compared to benign prostate tissue. Dataset with accession number GSE55945. Results
between different microarray studies are not comparable
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of the characteristics of their parental cells, such as andro-
gen sensitivity or metastatic potential, since MVs repre-
sent their source of cell origin. The common mRNAs in
MVs were first identified and validated in PCa EVs in our
study, and very limited number of reports previously iden-
tified those mRNAs in other cancer-derived EVs [35]. Fur-
thermore, another interesting finding was the possible
clinical relevance of ETV1 and FASN mRNA transcripts.
As determined by cluster analysis, ETV1 and FASN were
differential over-expressed in malignant prostate tissue in
comparison with benign biopsies, highlighting their
possible relevance as future cancer markers.
The majority of the transcriptomic reports studying EVs
utilize microarray analyses and deep sequencing to simul-
taneously examine the expression of thousands of genes
[6, 15–17]. While these technologies represent a great op-
portunity for clinical research, the results need further val-
idation [55, 56]. To our knowledge, this is the first study
showing and validating the changes in mRNA levels of 84
genes associated with PCa by RT-qPCR in different sub-
sets of PCa cell-derived EVs. The presented results pro-
vide important leads to identify specific markers in MVs
and EXOs isolated from both cancer cells and biofluids of
cancer patients, which could have a utility for cancer diag-
nosis and response monitoring of cancer treatments.
Conclusions
The mRNA cargo in EVs considerably differs based on
the EV subpopulation analyzed and the EV cellular ori-
gin, as different PCa cells and benign prostate epithelial
cells release very different mRNAs in their respective
EVs. The mRNA analyses performed in this study there-
fore provide new insights into the proportion of the cell
transcriptome that can be detected within EVs. The data
also emphasize the need to better dissect the role of EVs
and their cargo in cancer cell phenotype, putatively in
relation to progression of disease. Since the molecular
cancer signatures can be identified in EVs, their analysis
can contribute to the understanding of differences in
PCa heterogeneity. Whilst many previous studies have
focused on EV-associated miRNAs, this work demon-
strates the potential of the selective analysis of the
mRNA content of MVs and EXOs and highlights their
applicability in biomarker research.
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